Will 'Businessman' Trump See The Value In Indian Generics?
The election of Donald Trump as the next US president might suggest a degree of policy unpredictability for pharma companies but Indian firms are hoping that the businessman in the real estate mogul and President-elect will see the value that generics offer.
You may also be interested in...
Although Chinese President Xi Jinping has expressed the country's willingness to work with the newly elected US president to promote ties in a constructive way, potential setbacks for bilateral trade and regulatory talks are worrying observers.
The surprise decisive victory of Donald Trump in the US election has already been dubbed the "Trump Shock" by the mass media in Japan, where the pharma industry is largely waiting to see whether the new president's actions will match his rhetoric.
US biopharmas are holding billions in cash overseas to avoid paying America’s high corporate tax rate, so the prospect of a US tax holiday – or broad tax reform – will be welcomed by industry.